In recent years, with advances in molecular biology, novel immune checkpoint inhibitors targeting the programmed cell death-1 and its ligand (PD-L1) pathway have emerged as promising therapeutic options for PCNSL (3). Here, CD274 is linked to primary central nervous system lymphoma.